Hepatic veno-occlusive disease: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
Line 44: Line 44:


==References==
==References==
{{reflist}}
{{reflist|2}}


==Further reading==
==Further reading==

Revision as of 18:14, 4 September 2012

WikiDoc Resources for Hepatic veno-occlusive disease

Articles

Most recent articles on Hepatic veno-occlusive disease

Most cited articles on Hepatic veno-occlusive disease

Review articles on Hepatic veno-occlusive disease

Articles on Hepatic veno-occlusive disease in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hepatic veno-occlusive disease

Images of Hepatic veno-occlusive disease

Photos of Hepatic veno-occlusive disease

Podcasts & MP3s on Hepatic veno-occlusive disease

Videos on Hepatic veno-occlusive disease

Evidence Based Medicine

Cochrane Collaboration on Hepatic veno-occlusive disease

Bandolier on Hepatic veno-occlusive disease

TRIP on Hepatic veno-occlusive disease

Clinical Trials

Ongoing Trials on Hepatic veno-occlusive disease at Clinical Trials.gov

Trial results on Hepatic veno-occlusive disease

Clinical Trials on Hepatic veno-occlusive disease at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hepatic veno-occlusive disease

NICE Guidance on Hepatic veno-occlusive disease

NHS PRODIGY Guidance

FDA on Hepatic veno-occlusive disease

CDC on Hepatic veno-occlusive disease

Books

Books on Hepatic veno-occlusive disease

News

Hepatic veno-occlusive disease in the news

Be alerted to news on Hepatic veno-occlusive disease

News trends on Hepatic veno-occlusive disease

Commentary

Blogs on Hepatic veno-occlusive disease

Definitions

Definitions of Hepatic veno-occlusive disease

Patient Resources / Community

Patient resources on Hepatic veno-occlusive disease

Discussion groups on Hepatic veno-occlusive disease

Patient Handouts on Hepatic veno-occlusive disease

Directions to Hospitals Treating Hepatic veno-occlusive disease

Risk calculators and risk factors for Hepatic veno-occlusive disease

Healthcare Provider Resources

Symptoms of Hepatic veno-occlusive disease

Causes & Risk Factors for Hepatic veno-occlusive disease

Diagnostic studies for Hepatic veno-occlusive disease

Treatment of Hepatic veno-occlusive disease

Continuing Medical Education (CME)

CME Programs on Hepatic veno-occlusive disease

International

Hepatic veno-occlusive disease en Espanol

Hepatic veno-occlusive disease en Francais

Business

Hepatic veno-occlusive disease in the Marketplace

Patents on Hepatic veno-occlusive disease

Experimental / Informatics

List of terms related to Hepatic veno-occlusive disease

Hepatic veno-occlusive disease
Classification and external resources
ICD-10 K76.5
OMIM 235550
DiseasesDB 34365
eMedicine ped/2396 
MeSH D006504

Hepatic veno-occlusive disease or veno-occlusive disease (VOD) is a condition in which some of the small veins in the liver are obstructed. It is a complication of high-dose chemotherapy given before a bone marrow transplant (BMT) and is marked by weight gain due to fluid retention, increased liver size, and raised levels of bilirubin in the blood.[1] The name sinusoidal obstruction syndrome is now preferred if VOD happens as a result of chemotherapy or bone marrow transplantation.[1][2]

Apart from chemotherapy, VOD may also occur after ingestion of certain plant alkaloids such as pyrrolizidine alkaloids (in some herbal teas),[1] and has been described as part of a rare hereditary disease called hepatic venoocclusive disease with immunodeficiency (which results from mutations in the gene coding for a protein called SP110).[3]

History

The first report on veno-occlusive disease, in 1920, was as a result senecio poisoning in South Africa.[4] Subsequent reports were mostly in Jamaicans who had consumed herbal teas.[1] With the advent of bone marrow transplanation, most later reported cases have been in those undergoing treatment for leukemia.[1]

Pathophysiology

In the BMT setting, VOD is felt to be due to injury to the hepatic venous endothelium from the conditioning regimen.

Toxic agents causing veno-occlusive disease include plants as well as the medication cyclophosphamide.

Signs and symptoms

Features of VOD include weight gain, tender hepatomegaly, ascites, and increased bilirubin. It often is associated with renal failure.

Diagnosis

Hepatic doppler ultrasound is typically utilized to confirm or suggest the diagnosis. Most common findings on liver doppler ultrasound include increased phasicity of portal veins with eventual development of portal flow reversal. The liver is usually enlarged but maintained normal echogenicity. A liver biopsy is required for a definitive diagnosis.

Treatment

Treatment for VOD is primarily supportive. In the BMT setting, defibrotide is an investigational treatment that may be promising. Defibrotide is a polydeoxyribonucleotide isolated from pig intestine. Although its mechanism of action in VOD is unclear, the drug is believed to have antithrombotic properties. In August 2009, Gentium S.p.A., which sponsored the phase 3 clinical trial (pivotal) of defibrotide in hepatic VOD, announced disappointing results. Further clinical development of defibrotide for this indication is uncertain.

Prognosis

When associated with bone marrow transplant, VOD is fatal in over 30% of cases. Cases due to plant alkaloids often have a longer and more unpredictable course.

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 Helmy A (2006). "Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome". Aliment. Pharmacol. Ther. 23 (1): 11–25. doi:10.1111/j.1365-2036.2006.02742.x. PMID 16393276. Unknown parameter |month= ignored (help)
  2. DeLeve LD, Shulman HM, McDonald GB (2002). "Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)". Semin. Liver Dis. 22 (1): 27–42. doi:10.1055/s-2002-23204. PMID 11928077. Unknown parameter |month= ignored (help)
  3. Roscioli T, Cliffe ST, Bloch DB, (2006). "Mutations in the gene encoding the PML nuclear body protein Sp110 are associated with immunodeficiency and hepatic veno-occlusive disease". Nat. Genet. 38 (6): 620–2. doi:10.1038/ng1780. PMID 16648851. Unknown parameter |month= ignored (help)
  4. Willmot, F; Robertson, Georgew. (1920). "Senecio Disease, Or Cirrhosis Of The Liver Due To Senecio Poisoning". The Lancet. 196 (5069): 848. doi:10.1016/S0140-6736(01)00020-4.

Further reading

  • Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. ISBN 0-7216-0187-1.
  • Wingard JR, Nichols WG, McDonald GB (2004). "Supportive care". Hematology Am Soc Hematol Educ Program. 1: 372–89. doi:10.1182/asheducation-2004.1.372. PMID 15561693.

Template:Vascular diseases Template:Gastroenterology